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Key points
 Rheumatoid arthritis (RA) is a chronic inflammatory condition associated with an increased
risk of cardiovascular mortality.
 Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity heighten cardio-
vascular risk, althogh whether such autonomic dysfunction is present in RA is not known.
 In the present study, we observed an increased sympathetic nerve activity and reduced cardiac
baroreflex sensitivity in patients with RA compared to matched controls.
 Pain was positively correlated with sympathetic nerve activity and negatively correlated with
cardiac baroreflex sensitivity.
 The pattern of autonomic dysfunction that we describe may help to explain the increased
cardiovascular risk in RA, and raises the possibility that optimizing pain management may
resolve autonomic dysfunction in RA.
Abstract Rheumatoid arthritis (RA) is a chronic inflammatory condition associated with
increased cardiovascular morbidity/mortality and an incompletely understood pathophysiology.
In animal studies, central and blood borne inflammatory cytokines that can be elevated in
RA evoke pathogenic increases in sympathetic activity and reductions in baroreflex sensitivity
(BRS). We hypothesized that muscle sympathetic nerve activity (MSNA) was increased and
BRS decreased in RA. MSNA, blood pressure and heart rate (HR) were recorded in age-
and sex-matched RA-normotensive (n = 13), RA-hypertensive patients (RA-HTN; n = 17),
normotensive (NC; n = 17) and hypertensive controls (HTN; n = 16). BRS was determined
using the modified Oxford technique. Inflammation and pain were determined using serum high
sensitivity C-reactive protein (hs-CRP) and a visual analogue scale (VAS), respectively. MSNA
was elevated similarly in RA, RA-HTN and HTN patients (32 ± 9, 35 ± 14, 37 ± 8 bursts min–1)
compared to NC (22 ± 9 bursts min–1; P= 0.004). Sympathetic BRS was similar between groups
(P= 0.927), whereas cardiac BRS (cBRS)was reduced inRA, RA-HTNandHTNpatients [5(3–8),
4 (2–7), 6 (4–9) ms mmHg–1] compared to NC [11 (8–15) ms mmHg–1; P = 0.002]. HR was
independently associated with hs-CRP. Increased MSNA and reduced cBRS were associated with
hs-CRP although confounded in multivariable analysis. VAS was independently associated with
MSNA burst frequency, cBRS and HR. We provide the first evidence for heightened sympathetic
outflow and reduced cBRS in RA that can be independent of hypertension. In RA patients,
reported pain was positively correlated with MSNA and negatively correlated with cBRS. Future
studies should assess whether therapies to ameliorate pain and inflammation in RA restores
autonomic balance and reduces cardiovascular events.
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Abbreviations BMI, body mass index; BP, blood pressure; BRS, baroreflex sensitivity; cBRS, cardiac baroreflex
sensitivity; HR, heart rate; hs-CRP, high sensitivity C-reactive protein; HTN, hypertensive; IL, interleukin; MOT,
modified Oxford technique; MSNA, muscle sympathetic nerve activity; NC, normotensive controls; RA, rheumatoid
arthritis; RA-HTN, rheumatoid arthritis hypertensive; TNF, tumour necrosis factor; VAS, visual analogue scale.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
condition associated with increased risk of cardio-
vascular mortality and myocardial infarction, as well
as an increased prevalence of hypertension and cardiac
arrhythmias (Maradit-Kremers et al. 2005; Arosio et al.
2007; Levy et al. 2008; Panoulas et al. 2008). Traditional
cardiovascular risk factors are present in RA patients
but do not wholly account for the increased cardio-
vascular risk (Maradit-Kremers et al. 2005) and hence
novel mechanisms are sought (Amaya-Amaya et al. 2013;
Panoulas et al. 2014).
A heightened central sympathetic outflow to the heart
and/or vasculature has been identified in numerous
cardiovascular diseases (Fisher & Paton, 2012) and is
associatedwith the pathogenesis of hypertension (Fisher&
Paton, 2012), cardiac arrhythmias (Lown & Verrier, 1976)
and increased mortality (Cohn et al. 1984; Barretto et al.
2009). Reciprocal links between inflammation and the
sympathetic nervous system have been identified (Niijima
et al. 1991; Zhang et al. 2003; Helwig et al. 2008). Central
sympatholytic agents have anti-inflammatory actions
in human hypertension (Poyhonen-Alho et al. 2008),
whereas the infusion of inflammatory cytokines known
to be elevated in RA patients, such as interleukin (IL)-6
(Helwig et al. 2008), tumour necrosis factor (TNF)-α
(Zhang et al. 2003) and IL-1β (Niijima et al. 1991),
increases sympathetic nerve activity in rats. Thus, the
chronic activation of inflammatory cytokines in RA may
elicit deleterious increases in sympathetic neural outflow
that further promote activation of pro-inflammatory
cytokines. Furthermore, microinjection of IL-6 into the
nucleus of the solitary tract, a key central regulatory
cardiovascular site, is reported to reduce cardiac baroreflex
sensitivity (BRS) (Takagishi et al. 2010). Impaired BRS is
present in hypertension (Gribbin et al. 1971), heart failure
(Ferguson et al. 1992) and coronary artery disease (De
Ferrari et al. 2007), and is reported to predict reduced
survival following myocardial infarction (La Rovere et al.
1998; De Ferrari et al. 2007) and in patients with heart
failure (La Rovere et al. 2009). Depressed BRS may
potentially contribute to the recognized increased cardio-
vascular risk in RA (Maradit-Kremers et al. 2005; Levy
et al. 2008) by precipitating further increases in central
sympathetic outflow and reducing cardiac electrical
stability.
Whether sympathetic activity is increased and BRS is
reduced in RA is presently equivocal, partly as a result of
the indirect methods of assessment used to examine this
(Adlan et al. 2014). Elevations in plasma noradrenaline
have been reported in RA patients (Vlcek et al. 2008),
although it is not clear whether this is a consequence of
increased central sympathetic outflow, enhanced release
from peripheral adrenergic stores or altered local reuptake
mechanisms (Esler et al. 1990). Such limitations are
overcome by the microneurography technique, which
provides a direct assessment of sympathetic nerve activity
to the skeletal muscle vasculature (MSNA), although such
measures have not been undertaken previously in RA.
It is also not known whether baroreflex regulation of
MSNA is altered in RA. Although a reduction in cardiac
BRS has been suggested in RA patients (Aydemir et al.
2010), baroreflex control of the heart and vasculature do
not always function in a parallel fashion (Rudas et al.
1999).
We aimed to test the hypothesis that central sympathetic
outflow is elevated in RA patients and is associated with
elevated circulating concentrations of inflammatory cyto-
kines. We made the first direct recordings of MSNA in
patients with RA. Additionally, we examined whether
the sensitivity of baroreflex control of the heart and
MSNA are reduced in RA patients and associated with an
elevated concentration of circulating inflammatory cyto-
kines. Hypertension control groups (RA and non-RA)
were included to attempt and control for the effect of
medications and comorbidities.
Methods
Participants
Thirty patients with a clinical diagnosis of RA based on the
1987 American College of Rheumatology criteria (Arnett
et al.1988)were recruited from the rheumatology clinics at
Russells Hall Hospital, Dudley, UK, and Sandwell General
Hospital, West Bromwich, UK. The 1987 American
College of Rheumatology criteria allows for classification
of RA when four of its seven criteria (morning stiffness,
arthritis of three or more joint areas, arthritis of hand
joints, symmetric arthritis, rheumatoid nodules, positive
serum rheumatoid factor and radiographic changes)
are present (morning stiffness, arthritis and rheumatoid
nodules need to be present for at least 6 weeks). Exclusion
criteria included: age <18 or >75 years, atrial fibrillation
or other heart rhythm disorder, significant valvular
disease, coronary artery disease, diabetes, ischaemic
stroke, chronic renal failure, liver impairment, hormone
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replacement therapy, and those who are pregnant or
who might be pregnant. In addition, 33 age-, sex- and
body mass index (BMI)-matched control participants
were recruited from the hospitals and surrounding
areas. Normotensive control (NC) participants were
free from major illnesses, whereas hypertensive controls
(HTN) either had a prior diagnosis of hypertension or
blood pressure (BP) 140/90 mmHg. Ethical approval
was obtained by the local Research Ethics Committee
(National Research and Ethics Service Committee West
Midlands – Edgbaston, 11/WM/0298). Written informed
consent was received from participants prior to inclusion
in the study, in accordance with the Declaration of
Helsinki.
Experimental protocol
Participants were studied according to an observational,
case–control study that included four groups: 13 RA
patients, 17 RA-HTN patients, 16 HTN and 17 NC.
Participants attended the research laboratory at 09.00 h
after an overnight fast (from food, caffeine, alcohol and
nicotine). All medications were withheld on the morning
of testing. A detailed clinical history was obtained and
physical examination was performed in RA patients to
count the number of swollen and tender joints aiming
to determine the disease activity score C-reactive protein
(DAS28-CRP) (Wells et al. 2009). A visual analogue scale
(VAS) was used as a measure of patient-reported pain
(Huskisson, 1974). Height and weight was measured,
and the BMI was determined (weight/height2). All sub-
sequent measurements were performed under uniform
conditions in a temperature-controlled room when
the participants were resting quietly in the supine
position.
Following instrumentation for heart rate (HR), BP, leg
blood flow and MSNA as described below, an I.V. catheter
was inserted into a superficial vein in the antecubital
fossa for blood sampling and injections. The experimental
protocol involved a 10 min baseline period followed by
sequential infusion of sodium nitroprusside (100 μg of
sodium nitroprusside) and phenylephrine (150 μg of
phenylephrine) 1 min later (modified Oxford technique;
MOT) (Rudas et al. 1999).
Measurements
HR was continuously recorded using a lead II electro-
cardiogram (ECG, BioAmp; ADInstruments, Bella Vista,
Australia). Beat-to-beat BP was recorded using finger
photoplethysmography (Portapres; Finapres Medical
Systems, Amsterdam, The Netherlands) and was
calibrated with brachial BP recordings using an auto-
mated sphygmomanometer (Omron 705IT; Omron
Corporation, Hoopddorp, The Netherlands). Multi-unit
recordings of MSNA were obtained (FE185 NeuroAmp
EX; ADInstruments) from the peroneal nerve using
tungsten microelectrodes (200 μm, 1–3 μm uninsulated
tip; UNA32F2S; FHC, Bowdoin, ME, USA). Electrical
stimulation on the skin surface was used for nerve
mapping, and a reference electrode was inserted S.C.
2–3 cm away from the recording electrode, which was
inserted into the nerve fascicle. The neural signals were
amplified, filtered (100 Hz low pass, 2000 Hz high pass,
60 Hz notch), rectified and integrated (absolute value,
time constant decay 0.1 s) to obtain a mean voltage
of sympathetic nerve activity. MSNA was confirmed by:
listening to the amplified signal on speakers; observing
the characteristic bursting pattern on a computer screen;
palpating the skin and muscle fibres; and performing
a breath hold (Wallin & Fagius, 1988; Grassi & Esler,
1999). Leg blood flow was measured using venous
occlusion strain gauge plethysmography in accordance
with standardmethods (HokansonEC-6plethysmograph;
DE Hokanson, Bellevue, WA, USA) (Joyner et al. 2001). A
lightweight indium-in-silastic strain gauge was positioned
around the right calf at the point of greatest circumference.
The length of the strain gauge was 2 cm less than the
widest girth of the calf. Cuffs were placed around the
right ankle and inflated to a pressure of 200 mmHg and
maintained for 1 min to achieve arterial occlusion. Sixty
seconds later, cuffs placed around the thigh were rapidly
inflated to 50 mmHg (Hokanson E20 rapid cuff inflator
and AG101 air source; Hokanson, Bellevue, WA, USA) to
evoke venous occlusions. Venous occlusion was repeated
three times during 1 min, with the thigh cuffs inflated for
5 s and then deflated for 10 s each time.
Data analysis
Data were acquired using the Powerlab 16/35
data acquisition system and Labchart Pro software
(ADInstruments) andanalysedoffline. Sympathetic bursts
were identified by a single observer (AMA) using
a semi-automated scoring system created using Spike
2 (Cambridge Electronic Design, Cambridge, UK).
MSNA burst frequency (bursts min–1) and incidence
[bursts (100 heart beats)–1] was determined. Assessment
of cardiac BRS was determined during the phenylephrine
induced rise in BP (MOT) (Rudas et al. 1999; Studinger
et al. 2007). Analysis was performed from the first
concordant change in systolic BP and RR-interval
until they were discordant. To account for baroreflex
delays, systolic BP was associated with concurrent
(restingRR-interval>800ms) or subsequentRR-intervals
(RR-interval between 500 and 800 ms) (Pickering &
Davies, 1973; Eckberg & Eckberg, 1982). Respiratory
related variations in RR-interval were accounted for by
averaging RR-intervals over 3mmHgpressure bins (Ebert,
1990). Assessment of baroreflex control of MSNA was
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 1. Subject characteristics
RA RA-HTN NC HTN
(n = 13) (n = 17) (n = 17) (n = 16) P
Age (years) 55.9 ± 11.7 60.5 ± 9.6 53.6 ± 13.0 59.6 ± 10.1 0.257
Female, n (%) 8 (62) 12 (71) 10 (59) 11 (69) 0.876
Body mass index, (kg m–2) 27.8 29.6 26.4 25.8 0.130
(25.4–30.4) (26.4–33.3) (23.8–29.2) (24.5–27.2)
Total cholesterol (mmol L–1) 4.8 ± 1.1 5.1 ± 1.0 5.1 ± 0.9 5.1 ± 1.0 0.804
Triglycerides (mmol L–1) 1.1 (0.9–1.5) 1.0 (0.8–1.4) 1.1 (0.8–1.3) 1.1 (0.9–1.3) 0.968
HDL (mmol L–1) 1.3 (1.1–1.5) 1.5 (1.3–1.8) 1.4 (1.2–1.6) 1.4 (1.2–1.7) 0.498
LDL (mmol L–1)
a
2.9 ± 0.9 2.9 ± 0.9 3.1 ± 0.8 3.0 ± 0.9 0.866
eGFR (ml min–1 1.73 m–2) 100.4 ± 20.3 89.9 ± 14.6 88.0 ± 19.6 83.5 ± 17.9 0.099
Haemoglobin (g L–1) 126 ± 12∗ † 133 ± 14 138 ± 10 138 ± 12 0.019
Smoking, n (%) 4 (31) 1 (6) 3 (18) 0 0.064
Osteoarthritis, n (%) 2 (15) 9 (53) 0 4 (25) 0.003
Anti-hypertensive agent, n (%) – 7 (41) – 11 (69) 0.112
ACEi or ARB, n (%) – 5 (29) – 5 (31) 0.909
Calcium channel blocker, n (%) – 4 (24) – 7 (44) 0.218
Thiazide, n (%) – 2 (12) – 5 (31) 0.171
β-blocker, n (%) – 2 (12) – 1 (6) 0.582
α-blocker, n (%) – 0 – 2 (13) 0.133
Aspirin, n (%) 1 (8) 1 (6) 0 1 (6) 0.748
Statin, n (%) 1 (8) 6 (35) 0 4 (25) 0.032
Proton pump inhibitor, n (%) 4 (31) 6 (35) 0 1 (6) 0.016
Folic acid, n (%) 8 (62) 12 (71) 0 0 <0.001
Adcal D3, n (%) 2 (15) 5 (29) 1 (6) 0 0.060
Values are expressed as the mean ± SD (parametric) for continuous variables and frequency (percentage) for discrete variables.
Non-parametric data were (natural) log transformed and are displayed as the geometric mean (95% confidence intervals). One-way
ANOVA with a least significance difference post hoc test. Pearson’s chi-square test for categorical data. Significance: P  0.05. Post
hoc: P  0.05.
∗P  0.05 vs. HC
†P  0.05 vs. RA-HTN.
aCalculated using the Friedewald formula.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-renin blocker; CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Adcal D3 is a calcium carbonate, vitamin
D3 tablet.
determined using linear regression [diastolic BP (DBP) vs.
MSNA burst activity] during the phenylephrine induced
rise in BP (MOT) (Hart et al. 2010). Briefly, each cardiac
cycle was scored according to the presence or absence
of a sympathetic burst. Data were binned according to
the DBP of the previous cardiac cycle (3 mmHg bins).
Linear regression analysis was then performed on the
relationship between the mean of each DBP bin and
MSNA burst incidence (bursts/100 heart beats). All data
were weighted for the number of cardiac cycles in each
DBP bin (Hart et al. 2010). We used the slope of the
linear regression [(bursts/100 heart beats)/mmHg] as an
index of sympathetic BRS. Some patients were unsuitable
for microneurography (e.g. discomfort laying still for an
extended period or declined microneurography) and it
was not possible to obtain sufficiently high quality MSNA
recordings in all patients; thus, these results were omitted
fromtheMSNAanalyses. Participantnumbers are statedas
appropriate.
Blood sampling
Blood samples for inflammatorymarkerswere centrifuged
immediately and the plasma stored at –80°C.
Commercially available enzyme-linked immunosorbent
assay kits were used to determine high sensitivity
C-reactive protein (hs-CRP) (MPBiomedicals, Santa Ana,
CA, USA) and cytokines (IL-6, TNF-α, IL-10; BioSupply
UK, Bradford, UK). The intra- and inter-assay coefficients
of variationswere7.5%and4.1%, respectively, forhs-CRP;
4.9% and 6.0% for IL-6; 8.5% and 9.8% for TNF-α;
and 6.8% and 7.5% for IL-10. Local routine clinical
laboratories were used to analyse full blood count, renal
function, fasting lipid profile and fasting glucose.
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 2. Rheumatoid arthritis-related characteristics
RA RA-HTN
(n = 13) (n = 17) P
RA duration (years) 7.6 (4.6–12.4) 5.5 (2.9–10.5) 0.443
RF positive, n (%) 9 (69) 10 (59) 0.768
Swollen joints, n (%) 5.2 (2.9–9.0) 2.6 (1.6–4.0) 0.045
Tender joints, n (%) 6.7 (2.8–14.7) 3.5 (1.7–6.7) 0.194
DAS28-CRP 4.8 ± 1.9 3.7 ± 1.2 0.063
Disease activity, n (%)
Remission 4 (31) 5 (31) 0.088
Low disease activity 3 (23) 9 (56)
High disease activity 6 (46) 2 (13)
VAS, % 36.8 (21.7–62.0) 12.9 (5.3–30.1) 0.047
DMARD, n (%) 11 (85) 15 (88) 0.773
Number of DMARDs 1.8 (1.2–2.4) 1.8 (1.3–2.2) 0.850
Methotrexate, n (%) 8 (62) 12 (71) 0.602
Hydroxychloroquine, n (%) 5 (38) 10 (59) 0.269
Sulfasalazine, n (%) 4 (31) 3 (18) 0.400
Leflunomide, n (%) 2 (15) 1 (6) 0.390
Glucocorticoid, n (%) 1 (8) 6 (35) 0.077
Prednisolone, n (%) 1 (8) 4 (24) 0.249
Prednisolone dose (mg) 3 5.3 ± 3 0.534
Intramuscular, n (%) 0 1 (6) 0.374
Intra-articular, n (%) 0 1 (6) 0.374
NSAID, n (%) 5 (38) 6 (35) 0.858
Opioid, n (%) 6 (46) 7 (41) 0.785
Weak, n (%) 5 (38) 7 (41) 0.880
Strong, n (%) 1 (8) 0 0.245
Biological agent, n (%) 4 (31) 3 (18) 0.400
TNF-α inhibitor, n (%) 4 (31) 1 (6) 0.070
Certolizumab, n (%) 2 (15) 0 0.094
Etanercept, n (%) 2 (15) 0 0.094
Golilumab, n (%) 0 1 (6) 0.374
Rituximab, n (%) 0 2 (12) 0.201
Values expressed as the mean ± SD for continuous variables (parametric) and frequency (percentage) for discrete variables.
Non-parametric data were (natural) log transformed and are displayed as the geometric mean (95% confidence intervals). Statistical
differences were tested using an independent t test for continuous variables and Pearson’s chi-square test for categorical data.
Significance: P  0.05.
DAS, disease activity score; DMARD, disease modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; RF,
rheumatoid factor.
Statistical analysis
Statistical analysis was performed using SPSS, version 19
(IBM Corp., Armonk, NY, USA). Continuous variables
were tested for normality using the Kolmogorov–Smirnov
test.Non-parametric datawere (naturally) logarithmically
transformed. Group differences were assessed using
ANOVA with a least significance difference post hoc
test for continuous variables, as well as Pearson’s chi-
squared test for categorical data. Differences between
the RA normotensive and RA-HTN groups were
assessed using an independent t test. Associations
between autonomic parameters and inflammation were
assessed before (Pearson’s product/Spearman’s rank
correlation coefficient) and after adjustment for potential
confounders. Data are expressed as the mean ± SD for
parametric data; geometric mean (95% confidence inter-
val) for non-parametric data; and frequency (percentages)
for categorical variables. P < 0.05 was considered
statistically significant.
Results
Baseline participant characteristics are presented in
Table 1. Aside fromhypertension, therewere no significant
differences in other cardiovascular risk factors between
the groups. Compared to the RA and NC groups, there
was a higher prevalence of osteoarthritis (P = 0.003) and
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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statin therapy (P = 0.032) in the RA-HTN and HTN
groups. The RA and RA-HTN groups had a higher pre-
valence of proton pump inhibitor (P = 0.016) and folic
acid (P < 0.001) therapy, whereas calcium/vitamin D
supplementation tended to be highest in the RA-HTN
group (P= 0.06). Similar anti-hypertensive agent use was
noted in the RA-HTN and HTN groups. A small number
of participants were smokers (P= 0.064 between groups),
although no use of other nicotine containing products was
reported by any participant.
RA disease-related characteristics are presented in
Table 2. The RA normotensive and RA-HTN groups had
similar disease duration, sero-positivity and RA drug
therapy. A greater number of swollen joints (P = 0.045)
and a trend for higher disease activity (DAS28-CRP,
P = 0.063) were seen in the RA-HTN group compared
to the RA group.
Haemodynamic parameters
Mean BP was higher in the HTN and RA-HTN groups
compared to the RA and NC groups (P < 0.001),
with no significant difference between the RA-HTN
and HTN groups, or between the RA and NC groups
(systolic/diastolic BP RA 129 ± 10/79 ± 6, RA-HTN
154 ± 18/87 ± 10, HTN 147 ± 25/84 ± 11, NC
123 ± 10/75 ± 6 mmHg; P < 0.001; post hoc analysis,
P < 0.05 for RA vs. RA-HTN and HTN, NC vs. RA-HTN
and HTN; diastolic BP RA vs. HTN, P = 0.095) (Fig. 1).
Resting HR was higher in the RA and RA-HTN groups
compared to the NC andHTN groups (P= 0.008).MSNA
(burst frequency) was higher in the RA, RA-HTN and
HTN groups compared to the NC group (P = 0.004)
(Fig. 2). When adjusted for HR, there was a significant
difference in MSNA (burst incidence) between the groups
(P = 0.029). Post hoc analysis showed significantly higher
MSNA burst incidence in the HTN group compared
to the NC group; and trends for an elevation in the
RA-HTN vs. NC groups (P = 0.111) and between the
RA and HTN groups (P = 0.056) (Fig. 1). Leg blood flow
was significantly higher in the RA and RA-HTN groups
compared to the NC group and tended to be higher than
in the HTN group (geometric mean, 95% CI, RA 2.0,
1.5–2.6; RA-HTN 2.0, 1.4–2.8; NC 1.2, 0.9–1.7; HTN 1.4,
1.0–1.8 ml 100–1 ml min–1; P = 0.047; post hoc analysis
RA vs. HTN, P = 0.101, RA-HTN vs. HTN, P = 0.086).
However, leg vascular conductancewas similar between all
groups (RA 21, 15–27; RA-HTN 18, 12–26; NC 14, 10–19;
HTN 13, 10–17 arbitrary units; P = 0.148).
Baroreflex sensitivity
Cardiac BRS was lower in the RA, RA-HTN and HTN
groups compared to the NC group (P = 0.002), whereas
arterial baroreflex control of MSNA was not different
between all groups (P = 0.927) (Fig. 3).
Inflammation and pain
The RA and RA-HTN groups had higher hs-CRP
compared to the NC and HTN groups (P < 0.001)
(Fig. 4) with no significant difference between the RA
and RA-HTN groups. IL-6 was higher in the RA group
compared to the RA-HTN, NC and HTN groups, and was
higher in the RA-HTN group compared to the NC group
(P < 0.001). The RA group had higher TNF-α compared
to the NC and HTN groups (ANOVA, P = 0.027; post hoc
RA vs. NC and RA vs. HTN, P < 0.05) and numerically
(but not statistically significantly) higher TNF-α than the
RA-HTN group (post hoc RA vs. RA-HTN, P = 0.062).
IL-10 tended to be higher in the RA group compared to
the other groups (P = 0.159).
The RA and RA-HTN groups had more pain than the
NC and HTN groups (as measured by VAS) and the RA
group had more pain than the RA-HTN groups (RA
geometric mean 37, 95% CI 22–62; RA-HTN 13, 5–30;
NC 1, 0–2; HTN 1, 0–3; P < 0.001).
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Figure 1. BP and HR
Box and whisker plots showing mean blood
pressure (A, geometric mean and 95% confidence
intervals) and heart rate (B, mean ± SEM) in the
RA, RA-HTN, NC and HTN groups. Group (black
squares) and individual (white circles) data are
shown. Overall effect: P < 0.05. Post hoc:
∗P < 0.05 vs. NC, †P < 0.05 vs. HTN, ‡P < 0.05 vs.
RA-HTN. A and B, RA, n = 13; RA-HTN, n = 17;
NC, n = 17; HTN, n = 16.
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Associations between inflammation and autonomic
function
Inflammatory cytokines (IL-6, TNF-α and IL-10) were
positively associated with each other, whereas hs-CRP was
only associated with IL-6 (Table 3). Both hs-CRP and
IL-6 were positively associated with HR, although TNF-α
and IL-10 were not. MSNA burst frequency was positively
associated with hs-CRP but not with inflammatory cyto-
kines; however, this association was not evident when
MSNA was adjusted for HR (MSNA burst incidence).
Cardiac BRS was inversely associated with inflammation
(hs-CRP, IL-6 and TNF-α), whereas arterial baroreflex
control of MSNA was not.
Table 4 shows the association between inflammation
markers and autonomic function before and after
multivariable adjustment. Following multivariable
adjustment (RA, presence of hypertension, age, sex, BMI,
haemoglobin), hs-CRP remained positively associated
with HR (adjusted r2 = 0.375, P < 0.001), whereas
the associations with MSNA burst frequency and
cardiac BRS were no longer statistically significant.
Similarly, the associations between inflammatory
cytokines and autonomic parameters disappeared
following multivariable adjustment. In patients with
RA, disease activity (DAS28-CRP) was independently
associated with HR (adjusted r2 = 0.204, P = 0.034)
after adjustment for multiple variables (age, sex, BMI,
haemoglobin concentration, presence of hypertension
and RA duration).
Associations between pain and autonomic function
VAS was independently associated with MSNA burst
frequency (positively, P = 0.012), cardiac BRS (inversely,
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Box and whisker plots showing group mean ± SEM data for MSNA burst frequency (A) and MSNA burst incidence
(B), as well as original sympathetic neurograms showing MSNA (C) in representative individuals from the RA,
RA-HTN, NC and HTN groups. Group (black squares) and individual (white circles) data are shown. Overall effect:
P < 0.05. Post hoc: ∗P < 0.05 vs. NC. A and B, RA, n = 7; RA-HTN, n = 7, NC, n = 13; HTN, n = 11.
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P=0.044), andHR(positively,P<0.001) after adjustment
for multiple variables (RA, presence of hypertension, age,
sex, BMI, haemoglobin) (Table 4).
Discussion
In the present study, we provide the first direct evidence
for heightened sympathetic outflow and reduced arterial
baroreflex control of the heart in RA, whereas baroreflex
control of MSNA was preserved. These autonomic
alterations could occur independently of hypertension
and were associated with increases in both pain and
inflammation in RA.We show, in RA patients, thatMSNA
is heightened,whereas baroreflex control ofHR is reduced,
and also that this can occur independently of the presence
of hypertension. We observed a significant positive but
moderate association between inflammation (asmeasured
by hs-CRP) and MSNA.
Heightened sympathetic outflow to the heart and/or
vasculature can have a multitude of deleterious
consequences (Fisher & Paton, 2012) and is associated
with increased mortality risk (Lown & Verrier, 1976;
Cohn et al. 1984; Barretto et al. 2009). Experimental data
from animals showing that inflammatory cytokines (IL-6,
TNF-α, IL-1β) can increase sympathetic nerve activity
(Niijima et al. 1991; Zhang et al. 2003; Helwig et al. 2008)
led to our hypothesis that an elevated circulating cyto-
kine concentration is associated with increased MSNA
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Figure 3. Cardiovagal and arterial sympathetic baroreflex senstivity
Scatter plots from an original record of an RA patient demonstrating the relationship between RR-interval and
systolic BP (A), as well as between MSNA burst incidence and diastolic BP (B). Box and whisker plots showing
cardiovagal baroreflex sensitivity (C), geometric mean and 95% confidence intervals) and baroreflex control of
MSNA (D) (mean ± SEM) in the RA, RA-HTN, NC and HTN groups. Group (black squares) and individual (white
circles) data are shown. Overall effect: P < 0.05. Post hoc: ∗P < 0.05 vs. NC. A, RA, n = 13; RA-HTN, n = 17; NC,
n = 17; HTN, n = 16. B, RA, n = 6; RA-HTN, n = 5; NC, n = 9; HTN, n = 7.
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in RA. By using microneurography to provide a direct
assessment of sympathetic outflow, we circumvented the
limitations associated with the measurement of plasma
catecholamines, which reflect tissue clearance and uptake,
as well as production (Esler et al. 1990).
Reduced cardiac BRS is present in cardiovascular
diseases, such as hypertension and chronic heart
failure, and predicts mortality risk following myocardial
infarction (De Ferrari et al. 2007). Using the modified
Oxford technique, which provides an assessment of BRS
control across a wide BP range (Rudas et al. 1999), we
observed that cardiacBRSwas reduced inpatientswithRA.
The underlying mechanisms may relate to altered central
baroreflex modulation, as well as disruptions in afferent
or efferent pathways. Nevertheless, this reduced cardiac
BRS may contribute to the increased cardiovascular and
mortality risk seen in RA (Maradit-Kremers et al. 2005;
Levy et al. 2008). Interestingly, the baroreflex dysfunction
was specific to the cardiovagal limb because the control of
MSNA was not different between groups. The prognostic
significance of alterations in sympathetic BRS has not
been studied; however, baroreflex activation therapy has
been shown to reduce MSNA, improve symptoms and
increase ejection fraction in chronic heart failure patients
(Gronda et al. 2014). Studies of elderly individuals (Ebert
et al. 1992) and patients with HTN (Grassi et al. 1998)
have previously reported a differential effect on baroreflex
control of the heart and MSNA similar to that observed
in RA in the present study. Such observations may be
attributable to distinct baroreflex pathways regulating
different end-organs. This separation may commence at
the level of the primary afferent neurones and involve
discreet conduits within central reflex circuits that enable
the target-organ specific control of pre-motor and motor
neurones (Polson et al. 2007; Simms et al. 2006). In
addition, disparate changes in vagal and sympathetic
motoneuronal modulation, and/or cholinergic signalling
at the sinoatrial node, may also contribute (Rudas et al.
1999; Dutoit et al. 2010; Shantsila et al. 2015).
In the present study, pain was independently
associated with MSNA burst frequency and cardiac
BRS. These findings are in agreement with work
showing that experimentally evoked chronic pain can
heighten sympathetic outflow (Fazalbhoy et al. 2012)
and reduce cardiac BRS (Duschek et al. 2007). Although
the precise mechanisms are not fully understood,
interactions between pain and cardiovascular control may
be explained by an overlap in anatomical structures and
pathways, including afferent pathways (e.g. baroreceptor
and nociceptor projections), central modulation (e.g.
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Figure 4. Inflammatory biomarkers
Box and whisker plots showing concentrations (geometric
mean and 95% confidence intervals) of hs-CRP (A), IL-6
(B), TNF-α (C) and IL-10 (D) in the RA, RA-HTN, NC and
HTN groups. Group data are shown. Overall effect:
P < 0.05. Post hoc: ∗P < 0.05 vs. NC, †P < 0.05 vs. HTN,
‡P < 0.05 vs. RA-HTN. RA, n = 13; RA-HTN, n = 17; NC,
n = 17; HTN, n = 16.
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Table 3. Correlation between inflammation, pain and autonomic function
VAS hs-CRP IL-6 TNF-α IL-10
hs-CRP 0.586∗
<0.001 – – – –
57
IL-6 0.519∗ 0.339∗
<0.001 0.010 – – –
62 57
TNF-α 0.306∗ 0.010 0.753∗
0.016 0.939 <0.001 – –
62 57 62
IL-10 0.114 –0.068 0.537∗ 0.612∗
0.378 0.616 <0.001 <0.001 –
62 57 62 62
Heart rate 0.464∗ 0.362∗ 0.339∗ 0.059 −0.068
<0.001 0.006 0.010 0.646 0.616
63 57 57 57 57
Mean blood pressure 0.224 0.253 0.073 0.025 −0.138
0.077 0.057 0.572 0.844 0.286
63 57 62 62 62
MSNA burst frequency 0.238 0.418∗ 0.266 0.039 −0.044
0.150 0.011 0.107 0.816 0.794
38 36 38 38 38
MSNA burst incidence −0.032 0.193 0.039 −0.033 −0.109
0.849 0.260 0.815 0.844 0.516
38 36 38 38 38
cBRS −0.506∗ −0.332∗ −0.408∗ −0.322∗ −0.080
<0.001 0.019 0.002 0.016 0.561
55 50 55 55 55
Spearman’s correlation. Values are expressed as Spearman’s rho, P value and n.
∗Significance: P < 0.05.
nucleus of the solitary tract) and efferent pathways
(e.g. descending pain inhibitory, sympathetic and
parasympathetic projections) (Bruehl & Chung, 2004). In
the present study, RA patients had greater self-reported
pain than RA-HTN patients despite similar serum
concentrations of hs-CRP. Thismay reflect the higher pain
threshold observed in hypertensive individuals (i.e. hyper-
tensive hypoalgesia) (Ghione et al. 1988) or possibly an
effect of the higher concentration of inflammatory cyto-
kines in the RA group. Evidence from animal (Boettger
et al. 2008) and human studies shows that inflammatory
cytokines have a direct role in the modulation of pain
perception (Hess et al. 2011). TNF-α inhibition acutely
blocked both central nociceptive activity and activation
of the limbic system in RA patients (Hess et al. 2011).
In RA, disease control has been shown to improve
survival (Choi et al. 2002; Listing et al. 2015), although
further clarification is needed to distinguish between the
effects of pain and inflammation control on autonomic
function.
Elevated HR is an independent predictor of mortality
in the general population (Ho et al. 2014) and in other
conditions (e.g. chronic heart failure, coronary artery
disease, myocardial infarction, hypertension and diabetes
mellitus) (Palatini et al. 2002; Fox et al. 2008; Ho et al.
2010; Hillis et al. 2012; Jabre et al. 2014). Patients with
RA were observed to have an elevated HR in the present
study, independent of hypertension. Aside from an
increase in cardiac sympathetic nerve activity and a
decrease in parasympathetic activity, there are several
other potential mechanisms: chronic anaemia (Zlateva
et al. 2010), increased metabolic rate as a result of
chronic inflammation (Straub et al. 2010) or concomitant
thyroid dysfunction (Shiroky et al. 1993), medication
(Gilani et al. 2012), anxiety or depressive illness (Sheehy
et al. 2006) and low physical activity (Sokka et al. 2008).
Attempts to lowerHRwith the use of β-blockers following
myocardial infarction or in chronic heart failure has
been shown to improve survival (Lopez-Sendon et al.
2004). In an experimental model of arthritis, the use
of carvedilol (a non-selective β-blocker) was associated
with a reduction in markers of oxidative stress and the
release of inflammatory cytokines (TNF-α, IL-6) (Arab
& El-Sawalhi, 2013). Whether such benefits would be
manifest in RA patients treated with β-blockers requires
further study. We found that MSNA burst frequency
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Table 4. Association between inflammation (hs-CRP, IL-6, TNF-α and IL-10), pain (VAS) and autonomic function before and after
multivariable adjustment
Univariablea Multivariablec
N Rho P r2 F P
Dependent variable: MSNA burst frequency
hs-CRP 36 0.418 0.011 0.222 1.452 0.238
VAS 38 0.238 0.150 0.345 7.237 0.012∗
Dependent variable: cBRS
hs-CRP 50 −0.332 0.019 0.364 0.683 0.413
IL-6 55 −0.408 0.002 0.364 0.039 0.845
TNF-α 55 −0.322 0.016 0.364 0.055 0.815
VAS 55 −0.506 <0.001 0.417 4.279 0.044∗
Dependent variable: HR
hs-CRP 62 0.362 0.006 0.366 13.705 0.001∗
IL-6 62 0.339 0.010 0.208 0.230 0.634
DAS28-CRPd 29 0.499b 0.006 0.204 5.123 0.034∗
VAS 63 0.464 <0.001 0.526 36.661 <0.001∗
aSpearman’s rank.
bPearson’s correlation.
cAfter adjustment for age, sex, BMI, presence of hypertension, RA diagnosis and haemoglobin concentration.
dAfter adjustment for age, sex, BMI, presence of hypertension, haemoglobin concentration and RA duration.
DAS, disease activity score.
∗P < 0.05.
(bursts min–1) was higher in RA patients compared
to normotensive controls but MSNA burst incidence
[bursts (100 heart beats)–1] was not (RA vs. NC,P= 0.056;
RA-HTN vs. NC, P = 0.111), probably on account of the
elevated HR. Nevertheless, the observation that bursts
per unit time are elevated in RA and RA-HTN compared
to NC is interpreted as being indicative of heightened
sympatho-excitation. The relatively small sample size is a
potential limitation of the present study; however, this did
not prevent a significantly elevatedMSNAburst frequency
being detected in the RA, RA-HTN and HTN groups
compared to controls. A small number of participants
were smokers and, although the sympatho-excitatory
effects of smoking cannot be excluded (Hering et al. 2010),
smoking was not statistically associated with MSNA in
multivariable analysis.Notably, legbloodflowwas elevated
inRAandRA-HTNgroups compared to controls, possibly
as a result of the vasodilatory effects of inflammatory cyto-
kines. In animal models of sepsis, inflammatory cytokines
appeared to cause vasodilatation via downregulation of
α1-adrenergic, angiotensin II and vasopressin receptors
(Bucher et al. 2001; Bucher et al. 2002; Bucher et al. 2003).
We acknowledge that substantial variability was evident
in many of the parameters measured (e.g. inflammatory
cytokines, HR, cBRS). All data were tested statistically
for normality, and non-normally distributed data were
logarithmically transformed and parametric testing was
performed. In the multivariable analysis, independent
associations between pain VAS, hs-CRP and autonomic
function (HR, MSNA and cBRS) were weak to moderate
and only explained between 35% and 53% of the variance.
Further studies are required to determine the additional
factors that may contribute to autonomic dysfunction
in RA.
An important strength of the design of the present
study is the inclusion of hypertensive control groups,
allowing us to control for the presence of hypertension
in RA and to control for the effects of medications.
Athough increased MSNA and reduced cardiac BRS are
known to be present in hypertension (Carthy, 2014),
we have shown that, in RA, these autonomic alterations
can occur independently of hypertension, suggesting
an alternative mechanism (e.g. cortisol-induced hyper-
tension). Glucocorticoid use was higher in the RA-HTN
group compared to the RA group and may partly
account for the difference in the inflammatory profile
and BP seen in the present study. Glucocorticoids have
been shown to reduce MSNA (Lenders et al. 1995),
which may have attenuated sympatho-excitation in the
RA-HTN group. Mechanistic links between immunity
and hypertension have also been described, where T-cells,
macrophages and monocytes accumulate within the
kidney and blood vessel wall, releasing cytokines that
deleteriously affect renal and vascular function (McMaster
et al. 2015). The cross-sectional design precludes the
establishment of causality; however, we suggest that
heightened sympathetic outflow can occur prior to the
development of hypertension andmay possibly contribute
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to the development of hypertension in some patients
with RA. Autonomic dysfunction may be a causal factor
in the pathogenesis of RA or a consequence of the
disease, or both. Future randomized controlled inter-
ventional studies are needed to clarify whether auto-
nomic dysfunction is a cause or consequence of RA and,
in particular, to differentiate between the contributions
of inflammation and pain to autonomic dysfunction
in RA.
In conclusion, the present study is the first to
demonstrate heightened MSNA in RA. Heightened
sympathetic outflow and reduced baroreflex control of
HR in RA may potentially contribute to the recognized
increase in cardiovascular risk. We found that, compared
to inflammation, pain was more strongly correlated with
MSNA (positively) and cBRS (negatively), suggesting
a potential benefit in optimizing pain management to
restore autonomic balance in RA. Such findingsmaymean
that therapeutic interventions to reduce inflammation and
pain in RA can restore autonomic balance and hence
improve morbidity and mortality, whereas therapies that
target the autonomic nervous system (e.g. sympatholytic
agents, baroreflex activation) may reduce inflammation
and/or pain. Interventional studies designed to evaluate
these possibilities will help improve our understanding of
the pathophysiology of RA and, in particular, will shed
light on the interplay between inflammation, pain and the
autonomic nervous system.
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